Ask VialBase
other

Vesugen

Also known as: Lys-Glu-Asp, KED peptide
Preliminary evidence FDA: Not FDA-approved WADA: Not listed

Vesugen is a synthetic tripeptide (Lys-Glu-Asp, "KED") from the Khavinson bioregulator family — the vascular "Cytogen." It is studied as an epigenetic regulator of vascular endothelial cells, with reported anti-atherosclerotic and endothelial-repair effects and, more recently, effects on neurogenesis-related gene expression. Evidence is mostly in vitro and Russian-language; it is not FDA-approved. For educational purposes only. Not medical advice. Vesugen is the tripeptide Lys-Glu-Asp (KED). Its proposed action is epigenetic, focused on the vascular wall: 1. Endothelial gene regulation. KED is reported to modulate proliferation of vascular endothelial cells and the epigenetic regulation of that proliferation during ageing (PMID: 25051766).

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 390.4 Da
Half-life ~minutes estimated;
CAS number —
Route Subcutaneous · Oral subcutaneous preferred
02

Mechanism

Synthetic tripeptide (Lys-Glu-Asp, "KED") classed as a vascular "Cytogen" bioregulator. Proposed to act epigenetically on vascular endothelial cells — modulating proliferation and gene expression to support endothelial repair and reduce age-related vascular stiffening. Also studied for KED effects on neurogenesis-related gene expression. Evidence is largely in vitro and Russian-language, not FDA-grade.

03

Dosing

DOSE RANGE 10–20 mg per cycle
FREQUENCY 1×/day
CYCLE LENGTH 10–20 days, repeated 2–4×/year

Short pulsed Khavinson-style cycles, used in vascular-support protocols. Subcutaneous and oral routes are both described; no published bioavailability data.

04

Research summary

Study Type Year Key Finding
Molecular aspects of anti-atherosclerotic effects of short peptides Molecular (vascular) 2014 Short peptides including the vascular Cytogen showed anti-atherosclerotic molecular effects
Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis Molecular (vascular) 2016 KED (Vesugen) showed vasoprotective activity in atherosclerosis and restenosis contexts
Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease Molecular / review 2021 The KED tripeptide (Vesugen) was linked to molecular-genetic regulation of neurogenesis
05

Stacking & interactions

Vascular and tissue repair

Comprehensive vascular healing

Layered vascular bioregulation (Cytogen peptide + Cytomax complex)

06

Sourcing

Current prices

Updated today

20mg

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep
Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Lipid Panel
DURING CYCLE
  • Lipid Panel
POST-CYCLE
  • CMP
  • Lipid Panel
Safety & Regulatory Status
FDA STATUS Not FDA-approved
WADA STATUS Not listed

Regulatory status for Vesugen may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Vesugen?
Vesugen is a synthetic tripeptide (Lys-Glu-Asp, "KED") from the Khavinson short-peptide bioregulator family. It is the vascular "Cytogen," studied as an epigenetic regulator of endothelial cells for vascular repair and anti-atherosclerotic effects.
What does the research on Vesugen show?
The KED tripeptide has been studied in vitro for vasoprotective and anti-atherosclerotic effects, modulation of vascular endothelial cell proliferation, and — more recently — neurogenesis-related gene expression. Findings are mechanistic and mostly Russian-language; there are no FDA-registered clinical trials, so the evidence tier is preliminary.
What is Vesugen's peptide sequence?
Vesugen is the tripeptide Lys-Glu-Asp (KED), molecular weight ≈390 Da. It is one of the Khavinson Cytogens, related to Vilon (KE), Livagen (KEDA) and Epithalon.
How is Vesugen dosed?
Practitioner protocols use short pulsed courses of about 10–20 mg per cycle for 10–20 days, repeated two to four times a year, subcutaneously or orally. These are traditional Khavinson regimens, not trial-validated doses.
Is Vesugen FDA-approved?
No. Vesugen is not FDA-approved and is sold only as a research chemical. It is used in Russian cardiovascular bioregulator practice. Vascular-health claims are not supported by controlled human trials, and anyone with cardiovascular disease should be managed by a physician.

References

  1. Khavinson VKh et al.. Molecular aspects of anti-atherosclerotic effects of short peptides. Bull Exp Biol Med (2014). PMID: 25408528
  2. Kozlov KL et al.. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. Adv Gerontol (2016). PMID: 28539025
  3. Khavinson VK et al.. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. Bull Exp Biol Med (2021). PMID: 34173097